First human trial launches for new pill that activates immune system to fight cancer
NCT ID NCT05614102
Summary
This early-stage study is testing a new oral immunotherapy drug called BAY2965501 in people with advanced solid tumors that have spread and are hard to treat. Researchers want to find the safest dose and see how the body handles the drug, both alone and combined with other cancer treatments. The drug works by activating the body's own T-cells, a type of immune cell, to attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital | Oncology Department
Antwerp, 2650, Belgium
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, 518172, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
-
Clinica Universidad De Navarra | Oncologia
Madrid, 28027, Spain
-
Freeman Hospital
Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
Ghent University Hospital | Drug Research Unit Department
Ghent, 9000, Belgium
-
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
London, Greater London, SE1 9RT, United Kingdom
-
Hospital Hm Nou Delfos | Oncologia
Barcelona, 08023, Spain
-
Hospital Universitari Vall D Hebron | Oncologia
Barcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia
Madrid, 28050, Spain
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Oxford University Hospitals NHS Foundation Trust | Churchill Hospital - Oncology
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
START | San Antonio
San Antonio, Texas, 78229, United States
-
Samsung Medical Center - Oncology Department
Seoul, 135-710, South Korea
-
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
Denver, Colorado, 80218, United States
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
-
Severance Hospital, Yonsei University Health System - Oncology Department
Seoul, Seoul Teugbyeolsi, 03722, South Korea
-
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, 310016, China
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.